Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Authors: Bouriser J, Canivet CM, Costentin C et al.
Published in Clinical Gastroenterology and Hepatology (May 2023)
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Read MoreAre Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Exploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

Authors: Slusher AL, Hu P, Samuels S et al.
Published in Pediatric Obesity (December 2022)
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in recent years due to its direct link with obesity and type 2 diabetes (T2D).
Read MoreExploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Authors: Francque SM, Noureddin M, Krag A
Published in Clinical Gastroenterology and Hepatology (August 2023)
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Authors: Staels B, Butruille L, Francque S
Published in Journal of Hepatology (July 2023)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways. Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

Authors: Li YY, Zheng TL, Xiao SY et al.
Published in Liver International (June 2023)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
Read MoreBallooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

A brief introduction to the most promising pharmacological agents for NASH

Authors: Ratziu V and Tacke F
Published in Journal of Hepatology (July 2023)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASH

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES